Valneva, Pfizer Say Antibody Levels High For Lyme Disease Vaccine Candidate

Published on December 01, 2022 07:05 AM CET

Valneva, Pfizer Say Antibody Levels High For Lyme Disease Vaccine Candidate — Image source: ©2022 Kalkine Media®

Dec 1 (Reuters) - VALNEVA SE:

* VALNEVA AND PFIZER REPORT SIX-MONTH ANTIBODY PERSISTENCE DATA IN CHILDREN AND ADULTS FOR LYME DISEASE VACCINE CANDIDATE

* ANTIBODY LEVELS REMAINED ABOVE BASELINE SIX MONTHS AFTER COMPLETION OF A THREE-DOSE (MONTH 0-2-6) OR A TWO-DOSE (MONTH 0-6) VACCINATION SCHEDULE

* THERE WERE NO SAFETY CONCERNS OBSERVED IN THIS SIX-MONTH OBSERVATIONAL FOLLOW UP

* HIGHER ANTIBODY LEVELS WERE OBSERVED IN THE THREE-DOSE VACCINATION SCHEDULE VERSUS TWO-DOSE VACCINATION SCHEDULE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Reuters

Reuters -
93939 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.